Cargando…
Pin1 plays a key role in the response to treatment and clinical outcome in triple negative breast cancer
BACKGROUND: Triple negative breast cancer (TNBC) is the subset of breast cancer associated with the poorest outcome, and currently lacks targeted treatments. Standard of care (SoC) chemotherapy often consists of DNA damaging chemotherapies ± taxanes, with a range of responses observed. However, we c...
Autores principales: | Knowlson, Catherine, Haddock, Paula, Bingham, Victoria, McQuaid, Stephen, Mullan, Paul B., Buckley, Niamh E. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
SAGE Publications
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7065279/ https://www.ncbi.nlm.nih.gov/pubmed/32215056 http://dx.doi.org/10.1177/1758835920906047 |
Ejemplares similares
-
Controversial issues in the neoadjuvant treatment of triple-negative breast cancer
por: Fitzpatrick, Amanda, et al.
Publicado: (2019) -
Positive progress: current and evolving role of immune checkpoint inhibitors in metastatic triple-negative breast cancer
por: Simmons, Christine E., et al.
Publicado: (2020) -
Combined targeting EGFR and SRC as a potential novel therapeutic
approach for the treatment of triple negative breast cancer
por: Canonici, Alexandra, et al.
Publicado: (2020) -
Novel therapeutic avenues in triple-negative breast cancer: PI3K/AKT inhibition, androgen receptor blockade, and beyond
por: Chan, Jack J., et al.
Publicado: (2019) -
Cytotoxic T-lymphocyte infiltration and chemokine predict long-term patient survival independently of tumor mutational burden in triple-negative breast cancer
por: Katsuta, Eriko, et al.
Publicado: (2021)